Genmab A/S entered its second DuoBody deal with a large pharmaceutical firm inside two months. The Copenhagen, Denmark-based antibody developer entered a broad collaboration with the Johnson & Johnson subsidiary Janssen Biotech Inc. to develop bispecific antibodies against Janssen-supplied targets.
Genmab A/S entered its second DuoBody deal with a large pharmaceutical firm inside two months. The Copenhagen, Denmark-based antibody developer entered a broad collaboration with the Johnson & Johnson subsidiary Janssen Biotech Inc. to develop bispecific antibodies against Janssen-supplied targets. It is banking $3.5 million up front and could receive up to $175 million more in milestone and license payments for each successfully developed product.
DUBLIN, Ireland – Dublin's undpredictable weather, a confounding blend of sunshine, wind and rain, was an apt metaphor for the mix of optimism, realism and disappointment that could be heard in the many scientific sessions during the first full day of the Euroscience Open Forum 2012 (ESOF 2012) meeting at the Convention Centre Dublin Thursday.
CureBeta, the diabetes research alliance between Evotec AG and Doug Melton's lab in Harvard University's Department of Stem Cell and Regenerative Biology, has found an early taker for its preclinical portfolio of small molecules and biologics that can trigger growth of insulin-secreting pancreatic beta cells.
Opting for cash now rather than product sales later, Wilex AG decided to take a payment of $17.5 million as part of the deal it entered last year on the U.S. rights to its Phase III cancer antibody Rencarex (girentuximab) with Prometheus Laboratories Inc. It also stands to get another $2.5 million as part of a revised milestone payment that is contingent on a regulatory filing for the drug.
CureBeta, the diabetes research alliance between Evotec AG and Doug Melton's lab in Harvard University's Department of Stem Cell and Regenerative Biology, has found an early taker for its preclinical portfolio of small molecules and biologics that can trigger growth of insulin-secreting pancreatic beta cells.
DUBLIN ‑ Europe's biggest scientific carnival is pitching its tent beside the River Liffey this week. Dublin is playing host to the Euroscience Open Forum (ESOF) 2012 meeting and, thereby, assumes the mantle of Europe's City of Science for the year. Conceived as Europe's answer to the annual meeting of the American Association for the Advancement of Science, ESOF has become an increasingly visible element in Europe's efforts to foster a shared scientific identity. Although different European countries have vastly differing scientific heritages, their scientific futures are converging, thanks to an increasing level of recognition, both in Brussels and across...
Opting for cash now rather than product sales later, Wilex AG decided to take a payment of $17.5 million as part of the deal it entered last year on the U.S. rights to its Phase III cancer antibody Rencarex (girentuximab) with Prometheus Laboratories Inc. It also stands to get another $2.5 million as part of a revised milestone payment that is contingent on a regulatory filing for the drug.
Albireo AB licensed its constipation drug elobixibat to Ferring Pharmaceuticals SA for an undisclosed up-front fee, plus milestones and tiered double-digit royalties. Terms were not disclosed, but Ferring, of Saint-Prex, Switzerland, said it was one of its biggest product investment deals.
